MedTrace Logo

The Diabetes Virus Detection and Intervention Trial

NCT04838145 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2021-04-08

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled study in 96 children and adolescents age 6-15 newly diagnosed with type 1 diabetes to describe the influence of antiviral treatment (Pleconaril and Ribavirin) on progression of disease and residual insulin secretion.

Conditions

  • Type1 Diabetes Mellitus
  • Enterovirus

Interventions

DRUG

Ribavirin + Pleconaril

Randomized to treatment with study drugs (ribavirin and pleconaril)

DRUG

Placebos

Randomized to treatment with placebo

Sponsors & Collaborators

  • Oslo University Hospital

    lead OTHER

Principal Investigators

  • Knut Dahl-Jørgensen, MD, PhD · Professor

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-30
Primary Completion
2020-10-25
Completion
2020-10-25

Countries

  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04838145 on ClinicalTrials.gov